SRA's number for the day: 2,325,000
This article was originally published in SRA
The US Food and Drug Administration's fee for manufacturers who want to use the agency's priority review voucher program for drugs for tropical diseases will rise to $2,325,000 in fiscal year 20141.
You may also be interested in...
Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include five new products, including Lumoxiti, AstraZeneca's drug for hairy cell leukemia. The list, which contains information dating back to January 2018, comprises brand name, generic name, company, therapeutic indication, date of marketing authorization announcement and product type (eg, medicine, vaccine, biologic).
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.